Regeneron struck a drug pricing deal with the Trump administration on Thursday, agreeing to lower costs for some American ...

If the crackdown on pharma’s TV ads and subsequent extension to social media has underscored anything, it’s that brands need ...

President Donald Trump will be announcing a drug pricing deal with Regeneron at the White House on Thursday at 3 p.m., ...

With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer’s GLP-1 weight management treatment Xianweiying is available for pre-order in China, ​a Reuters check on a local ...

The institute said the NHS should make this combo available to patients after weighing its safety and efficacy against Tafinlar and Mekinist, the current standard treatment.

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...